# Salvatore Siena

Source: https://onco.cc/people/salvatore-siena/  
OnCo record `salvatore-siena` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Milan oncologist who co-led HERACLES and was lead author of DESTINY-CRC01, which showed trastuzumab deruxtecan is active in HER2-positive colorectal cancer, and a leader of the anti-EGFR antibody trials in the disease.

## Summary

Salvatore Siena is professor of medical oncology at the University of Milan and led the Niguarda Cancer Center's oncology programme. He was a senior investigator of HERACLES and first author of the 2021 Lancet Oncology report of DESTINY-CRC01, the phase 2 trial in which trastuzumab deruxtecan produced responses in HER2-positive, RAS wild-type metastatic colorectal cancer after standard therapy. He was also a lead investigator of the panitumumab trials that established RAS testing before anti-EGFR treatment.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: colorectal; targeted-therapy; trialist
- Role: Professor of Medical Oncology, University of Milan, and Niguarda Cancer Center
- Specialisms: Colorectal cancer; HER2-directed therapy; Anti-EGFR therapy

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Salvatore_Siena

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [HER2-amplified colorectal cancer](https://onco.cc/cancers/her2-amplified-colorectal/)
- institutions: [Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda](https://onco.cc/institutions/niguarda-cancer-center/)
- trials: [HERACLES](https://onco.cc/trials/heracles/)
- key papers: [Assessment of a HER2 scoring system for colorectal cancer: results from a validation study](https://onco.cc/key-papers/paper-valtorta-her2-scoring-colorectal-heracles-mod-pathol-2015/), [Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES)](https://onco.cc/key-papers/paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016/), [Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer](https://onco.cc/key-papers/paper-misale-kras-acquired-resistance-anti-egfr-colorectal-nature-2012/), [Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer (PRIME)](https://onco.cc/key-papers/paper-douillard-prime-panitumumab-ras-nejm-2013/), [Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01)](https://onco.cc/key-papers/paper-siena-destiny-crc01-trastuzumab-deruxtecan-lancet-oncol-2021/), [Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER)](https://onco.cc/key-papers/paper-strickler-mountaineer-tucatinib-trastuzumab-lancet-oncol-2023/)

---
JSON: https://onco.cc/api/v1/entities/salvatore-siena.json